HIF1A and neoplasm: Regarding the perioperative administration of NSAIDs, a pilot study of 45 patients with prostate cancer randomized to celecoxib 400 mg BD or no treatment for 4 weeks before radical prostatectomy found that celecoxib decreased tumor cell proliferation, micro-vessel density, angiogenesis, and HIF-1 while enhancing apoptosis (53).